Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A

What Was Tested

The trial (phase 3) is built around Cetrorelix for pcos.

This randomized trial aims to compare the euploid rate of blastocysts between PPOS (progestin-primed ovarian stimulation) and GnRH (gonadotrophin releasing hormone) antagonist protocols in patients with PCOS (polycystic ovary syndrome) undergoing PGT-A (preimplantation genetic testing for aneuploidy).

Infertile women with PCOS will be recruited for study after explanation and counseling if they fulfill the inclusion criteria and do not have the exclusion criteria.

Eligible women will be randomised into one of the two groups: Antagonist group: Women will receive antagonist once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.

It had two arms (groups): Antagonist group (active comparator) and PPOS group (experimental).

The registry classes the interventions as drug.

Who Took Part

Enrollment: 204 planned participants were the target.

It was open to women only aged from 20 years up to 37 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Women age between 20 and 37 years.

The full record lists 2 inclusion and 7 exclusion criteria; among the exclusions: presence of a functional ovarian cyst with e2\>100 pg/ml; endometriosis grade 3 or higher; repeated implantation failure (\>=4 embryos replaced or \>=2 blastocysts replaced without success).

How the Study Was Run

The set-up was randomized, parallel-group and open-label.

The pcos participants were allocated by chance, so the Cetrorelix group and the comparison group should start out alike.

Groups ran in parallel: each of the pcos participants stayed in one arm throughout.

Nothing was hidden in this open-label Cetrorelix study: the pcos participants and staff both knew the treatment.

It started in 2026-06-01 with completion listed for 2027-12-01.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: euploidy rate (time frame: 1 month after oocyte retrieval).

It also tracked 6 secondary outcomes, for example live birth rate, cumulative live birth rate, ongoing pregnancy, number of oocytes retrieved, OHSS（ovarian hyperstimulation syndrome） and birthweight of newborns.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Cetrorelix in 204 people with pcos.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Cetrorelix compound page, PCOS research.